Huawei Medicine Technology Group successfully invalidates Fuji’s innovative drug patent, new time of anti-gout drug comes

The Patent Reexamination Board (PRB) of CNIPA recently made a decision on Huawei Medicine Technology Group’s request for invalidation of the Japanese Fuji Pharmaceuticals' “TopiroxostatCrystal Form Patent” and declared the total invalidation of the invention patent CN104411700B (patent application No. 201380035675.3). Thus the innovative crystal form patent technology has lost its patent right in China, accelerating the arrival of a new time of Chinese anti-gout drugs.